Innova Captab Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
INNOVACAP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.4 pts more than Nifty Microcap 250 and 1.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Innova Captab Limited reported consolidated revenue of ₹16,300.18 million for FY2026, up 31% from ₹12,436.76 million in FY2025. Profit after tax grew 9.9% to ₹1,409.17 million from ₹1,282.58 million. On a standalone basis, revenue increased 35% to ₹12,958.14 million, though PAT declined 6.5% to ₹836.92 million due to higher expenses. The statutory auditor B S R & Co. LLP issued an unmodified (clean) opinion on both standalone and consolidated results. The company operates in a single segment - drugs and pharmaceuticals. The Board also approved amendments to the Related Party Transactions policy.
Strong revenue growth of 31% on consolidated basis indicates solid business expansion, though standalone PAT decline raises concerns about cost efficiency at the parent level. Clean audit opinion removes any concerns about financial reporting quality.